Similarly to the situation described above for Th9 cells, mice genetically deficient for IL-17R or treated with IL-17R-Ig fusion protein develop less severe IBD upon treatment with TNBS [182], suggesting that the protective role of IL-17 may depend on the specific colitis model and the local microenvironmental inflammatory conditions. This evidence concerns the gene IL17A and inflammatory bowel disease.